The successful use of rituximab in IgA nephropathy patients with podocytopathy: a case series.
在具有足細胞病變的 IgA 腎病患者中成功使用 rituximab:病例系列。
Clin Kidney J 2024-08-09
Efficacy and safety of long-term repeated use of rituximab in pediatric patients with nephrotic syndrome.
青少年腎症患者長期重複使用利妥昔單抗的療效和安全性。
Pediatr Nephrol 2024-02-06
Efficacy of Rituximab for Minimal Change Disease and Focal Segmental Glomerulosclerosis with Frequently Relapsing or Steroid-Dependent Nephrotic Syndrome in Adults: A Chinese Multicenter Retrospective Study.
成人常反覆復發或依賴類固醇的輕度變化疾病和局灶性節段腎小球硬化症的利妥昔單抗療效:中國多中心回顧性研究。
Am J Nephrol 2024-02-06
Oral glucocorticoids with intravenous cyclophosphamide or oral glucocorticoids alone in the treatment of IgA nephropathy present with nephrotic syndrome and mesangioproliferative glomerulonephritis.
口服糖皮質類固醇搭配靜脈注射環磷酰胺,或僅口服糖皮質類固醇治療伴有腎病症候群和系膜增生性腎小球腎炎的IgA腎病。
Clin Kidney J 2023-12-05
Early Rituximab as an Add-On Therapy in Children With the Initial Episode of Nephrotic Syndrome.
兒童首次發作腎症候群的早期補充療法:Rituximab。
Kidney Int Rep 2024-05-06
Efficacy of rituximab and risk factors for poor prognosis in patients with childhood-onset steroid-resistant nephrotic syndrome: a multicenter study.
兒童發病期類固醇抗藥性腎症患者利妥珠單抗的療效及不良預後風險因素:多中心研究。
Pediatr Nephrol 2024-06-04
The efficacy and safety of rituximab with or without glucocorticoid in inducing remission of MCD with different clinical presentations in adults: a retrospective study.
成人不同臨床表現的MCD患者中,利妥昔單抗單獨或聯合糖皮質激素誘導緩解的療效和安全性:一項回顧性研究。
Clin Kidney J 2024-06-10